Ignite Creation Date:
2025-12-24 @ 10:51 PM
Ignite Modification Date:
2026-01-04 @ 6:20 AM
Study NCT ID:
NCT02879669
Status:
UNKNOWN
Last Update Posted:
2020-10-08
First Post:
2016-07-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Sponsor:
Targovax Oy
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-06
Start Date Type:
None
Primary Completion Date:
2020-05
Primary Completion Date Type:
ACTUAL
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2016-07-13
First Submit QC Date:
None
Study First Post Date:
2016-08-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-10-06
Last Update Post Date:
2020-10-08
Last Update Post Date Type:
ACTUAL